1955年磺酰脲类出现以来,开发了许多口服降血糖药。这些口服降血糖药虽能降低血糖,但有促使血管并发症进展的可能性。因此,最近的开发工作以同时具有防止糖尿病性血管并发症的作用的化合物为中心。法国Servier研究所发现的磺酰脲同时有降血糖和抑制血小板粘附的作用,最后选择甲磺吡脲(Gliclazide)进行广泛的基础及临床试验。日本也在1973年由大日本制药公司进行研究,1984年5月开始出售。本品是控制非胰岛素依赖性糖尿病的高效药物。大鼠、豚鼠、兔、狗口服本品后,因促进胰岛素分泌而使血糖下降,其作用是甲磺丁脲 Since the advent of sulfonylureas in 1955, many oral hypoglycemic agents have been developed. Although these oral hypoglycemic agents can lower blood sugar, but may promote the possibility of vascular complications. Therefore, recent developments have focused on compounds that simultaneously have the effect of preventing diabetic vascular complications. Sulphonylureas found in France’s Servier Institute have both hypoglycemic and anti-platelet adhesion effects. Finally, Gliclazide is selected for extensive basic and clinical trials. Japan was also studied by Japan’s largest pharmaceutical company in 1973 and was sold in May 1984. This product is a highly effective drug to control non-insulin-dependent diabetes. Rats, guinea pigs, rabbits, dogs after oral administration of this product, due to the promotion of insulin secretion and blood glucose decreased, its role is metolachlor